Form 4: Privia Health CEO Boosts Stake After RSU, PSU Vesting

Privia Health Group, Inc. CEO Parth Mehrotra increased his beneficial ownership significantly following the vesting of restricted and performance stock units, alongside a planned sale.

Summary

• Parth Mehrotra, Chief Executive Officer and Director of Privia Health Group, Inc. (PRVA), reported changes in his beneficial ownership.
• On March 10, 2026, Mr. Mehrotra sold 21,097 shares of common stock at a weighted average price of $22.71 per share, with prices ranging from $22.27 to $23.23, as part of a Rule 10b5-1 trading plan.
• Also on March 10, 2026, Mr. Mehrotra acquired 141,342 shares of common stock at a price of $0, reflecting the vesting of restricted stock units (RSUs) granted under the 2021 Omnibus Incentive Plan.
• On March 11, 2026, Mr. Mehrotra acquired an additional 171,904 shares of common stock at a price of $0, representing the vesting and distribution of performance stock units (PSUs) for the 2023-2025 performance period.
• The PSU vesting included 141,948 shares from units granted on May 9, 2023, and 29,956 shares from units granted on July 1, 2023.
• Following these transactions, Mr. Mehrotra's direct beneficial ownership increased from 343,795 shares (before the sale) to 635,944 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as moderately positive due to the substantial increase in the CEO's beneficial ownership through equity awards, despite a minor planned sale, indicating strong alignment with shareholder interests.

Positives

• Significant vesting of 141,342 restricted stock units and 171,904 performance stock units indicates the achievement of performance targets and continued executive compensation alignment.
• The net effect of the transactions is a substantial increase in the CEO's beneficial ownership, from 343,795 shares to 635,944 shares, demonstrating increased alignment with shareholder interests.

Negatives

• An insider sale of 21,097 shares, even if pre-planned under Rule 10b5-1, can sometimes be perceived negatively by the market.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance, focusing solely on insider transactions.

Management Comments

• The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

Industry Context

StockSavvy.ai notes that insider transactions, particularly the vesting of equity awards, are a standard component of executive compensation in the healthcare services sector. These transactions align executive incentives with long-term company performance and are routinely disclosed via Form 4 filings.

Stakeholder Impact

• Shareholders may view the significant increase in the CEO's beneficial ownership as a positive sign of management's continued commitment and alignment with long-term company performance.

Next Steps

• Restricted stock units under the 2021 Omnibus Incentive Plan will vest in substantially equal annual installments on the first, second, and third anniversaries of the grant date, generally subject to continued service.

Key Dates

Recommendation

The filing indicates a significant increase in the CEO's beneficial ownership through equity awards, which aligns management interests with shareholders. While there was a planned sale, the net effect is positive for insider alignment. This suggests a stable outlook rather than a strong buy or sell signal based solely on these transactions, warranting a 'hold' recommendation for existing investors.

Keywords

Privia Health, PRVA, Insider Trading, Form 4, Equity Compensation, Restricted Stock Units, Performance Stock Units, CEO, Beneficial Ownership, Rule 10b5-1